

Submission to the Pharmaceutical Benefits Advisory Committee on obesity medicines and the role of APDs

Dietitians Australia has provided a submission to the Pharmaceutical Benefits Advisory Committee on 1) equitable access to glucagon-like peptide-1 (GLP-1) receptor agonist medicines through the Pharmaceutical Benefits Scheme for the treatment of obesity; and 2) SEMAGLUTIDE - Wegovy: Established cardiovascular disease with obesity. We call on the Government to: 1. Require referral to an APD before and on prescription of GLP-1 RA medicines for any therapeutic purpose. 2. Ensure consumer access to APDs before, during and after using GLP-1RA medicines.

To read more, [download](#) our full submission.

Get in touch

If you have questions about this position statement, contact us at policy@dietitiansaustralia.org.au